Findings from CONFIRM - a large real-world evidence study - compared the effectiveness of Tresiba injections versus insulin glargine U300, marketed as Toujeo and sold by Sanofi. The study included ...

Tresiba (insulin degludec) and Fiasp (insulin aspart), by more than 70% starting Jan. 1, 2026. Fiasp's price will be reduced by 75%, making it the same price as NovoLog (insuin aspart), while ...

DEVOTE showed Tresiba was on a par with Lantus in ... Fiasp is a formulation of insulin aspart (NovoLog) developed with the aim of obtaining pharmacokinetic and pharmacodynamic properties that ...